COVID-19 Disease Severity Risk Factors for Pediatric Patients in Italy.


Journal

Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422

Informations de publication

Date de publication:
10 2020
Historique:
accepted: 09 07 2020
pubmed: 16 7 2020
medline: 21 10 2020
entrez: 16 7 2020
Statut: ppublish

Résumé

To describe the epidemiological and clinical characteristics of coronavirus disease (COVID-19) pediatric patients aged <18 years in Italy. Data from the national case-based surveillance system of confirmed COVID-19 infections until May 8, 2020, were analyzed. Demographic and clinical characteristics of subjects were summarized by age groups (0-1, 2-6, 7-12, 13-18 years), and risk factors for disease severity were evaluated by using a multilevel (clustered by region) multivariable logistic regression model. Furthermore, a comparison among children, adults, and elderly was performed. Pediatric patients (3836) accounted for 1.8% of total infections (216 305); the median age was 11 years, 51.4% were male, 13.3% were hospitalized, and 5.4% presented underlying medical conditions. The disease was mild in 32.4% of cases and severe in 4.3%, particularly in children ≤6 years old (10.8%); among 511 hospitalized patients, 3.5% were admitted in ICU, and 4 deaths occurred. Lower risk of disease severity was associated with increasing age and calendar time, whereas a higher risk was associated with preexisting underlying medical conditions (odds ratio = 2.80, 95% confidence interval = 1.74-4.48). Hospitalization rate, admission in ICU, disease severity, and days from symptoms onset to recovery significantly increased with age among children, adults and elderly. Data suggest that pediatric cases of COVID-19 are less severe than adults; however, age ≤1 year and the presence of underlying conditions represent severity risk factors. A better understanding of the infection in children may give important insights into disease pathogenesis, health care practices, and public health policies.

Identifiants

pubmed: 32665373
pii: peds.2020-009399
doi: 10.1542/peds.2020-009399
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 by the American Academy of Pediatrics.

Déclaration de conflit d'intérêts

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

Auteurs

Stefania Bellino (S)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy; stefania.bellino@iss.it.
Contributed equally as co-first authors.

Ornella Punzo (O)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Contributed equally as co-first authors.

Maria Cristina Rota (MC)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Martina Del Manso (M)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Alberto Mateo Urdiales (AM)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Xanthi Andrianou (X)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Massimo Fabiani (M)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Stefano Boros (S)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Flavia Riccardo (F)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Antonino Bella (A)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Antonietta Filia (A)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Giovanni Rezza (G)

General Directorate for Prevention, Ministry of Health, Rome, Italy; and.

Alberto Villani (A)

General Pediatrics and Infectious Diseases Unit, Pediatric Hospital Bambino Gesù, Rome, Italy.

Patrizio Pezzotti (P)

Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH